Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
March 2021
-
Media Release
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad… -
Key Release
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive… -
Featured News
Novartis inaugurates innovative watershed project in India to increase water availability
Together with local partners, Novartis aims to initiate a watershed development project near its own and supply chain operations in the Telangana region.
-
Story Access to Healthcare
Novartis joins pharma-wide effort to meet global demand for COVID-19 vaccines
A conversation with Joachim Momm, head of a Novartis manufacturing site that will be helping to produce Pfizer-BioNTech vaccine doses.
-
Key Release
Novartis appoints Karen Hale as Chief Legal Officer
Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive… -
Featured News
Highlights from the Co-Creating Impact Summit 2020
The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.
-
Media Release
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,… -
Key Release
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed… -
Featured News
EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare
Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.
-
Story People and Culture
Challenging a young scientist to focus on patients
Novartis researcher Joana Silva had a life-changing experience with a mentor.
-
Story People and Culture
Teaching a daughter the power of purpose
Racey Muchilwa, Head of Sub-Saharan Africa for Novartis, reflects on her mother’s calling as a teacher.
-
Story People and Culture
Inspiring a daughter to make her own path
Chief Talent and People Solutions Officer Tripti Jha’s mother prioritized her learning in a rural region of India with limited opportunities for girls.